Given limited information at market authorization, combined with the speed at which vaccination will take place, upcoming mass vaccination programs for COVID-19 will be associated with a significant spike in adverse event reporting. The pharma industry must plan its response to gathering data on the safety of both vaccines and medicines used with them in response to this unprecedented global campaign. Pharmacovigilance teams across all companies must be prepared.
Sidley partners Torrey Cope, Heidi Levine, and Michelle Ramirez contributed to this white paper authored by Dr. Andrew Rut, CEO and co-founder of MyMeds&Me, founded by Senior Pharma executives to transform safety data capture, processing and reporting through a digital platform.
